HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.

Yamaoka, Toshimitsu; Tsurutani, Junji; Sagara, Hironori; Ohmori, Tohru

Yamaoka, Toshimitsu; Tsurutani, Junji; Sagara, Hironori; Ohmori, Tohru.

Afiliação

Yamaoka T; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
Tsurutani J; Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Sagara H; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
Ohmori T; Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Transl Lung Cancer Res ; 9(5): 2178-2183, 2020 Oct.

Article em En | MEDLINE | ID: mdl-33209639

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão País de publicação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google